-
-
-
-
-
-
-
Windtree Announces Publication of Istaroxime Positive Phase 2 SEISMiC B Study
-
-
-
-
-
-
-
Windtree Therapeutics (WINT) Announces Plan for Cryptocurrency Treasury Policy
-
-
-
-
-
-
-
Windtree Announces Istaroxime Exclusivity and Intellectual Property Potential Strategy for US
-
-
-
-
-
-
-
Windtree Therapeutics, Inc. (WINT) Announces License and Supply Agreement to Become Sourcing Partner for a Small Biotech with an FDA Approved Product
-
-
-
-
-
-
-
Windtree Therapeutics (WINT) Announces Special Late-Breaking Clinical Science Abstract Presentation on Istaroxime at the Technology and Heart Failure Therapeutics Conference
-
-
-
-
-
-
-
Windtree Announces Istaroxime Presentation By Cardiogenic Shock Thought Leader At Cardiovascular Clinical Trials Conference
-
-
-
-
-
-
-
Windtree Therapeutics Initiates SEISMiC C Study of Istaroxime in SCAI Stage C Cardiogenic Shock for Planned Completion of Phase 2b and Transition to Phase 3
-
1,157,766 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

